Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.69% is 66% above its 3-year average of -69.18%, near the high end of its 3-year range (-188.17%–-8.05%).
75.85% above its 12-month average of -98.11%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.27%.
RETURN ON ASSETS (ROA)
-23.69%
RETURN ON ASSETS (ROA) AVG TTM
-98.11%
RETURN ON ASSETS (ROA) AVG 3Y
-69.18%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+75.85%
CURRENT VS 3Y AVG
+65.76%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-27.69%
median of 556 covered companies
CURRENT VS SECTOR MEDIAN
+14.43%
vs the sector median at left
LB Pharmaceuticals Inc Common Stock
Market Cap
$986.19M
Return on Assets (ROA)
-23.69%
TTM Avg
-98.11%
3Y Avg
-69.18%
5Y Avg
N/A
Market Cap
$1.00B
Return on Assets (ROA)
19.92%
TTM Avg
-50.75%
3Y Avg
-41.99%
5Y Avg
-34.79%
Market Cap
$1.00B
Return on Assets (ROA)
-0.20%
TTM Avg
-7.25%
3Y Avg
-2.02%
5Y Avg
0.01%
Market Cap
$999.08M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Return on Assets (ROA)
-10.18%
TTM Avg
-8.89%
3Y Avg
-12.61%
5Y Avg
-16.81%
Market Cap
$1.01B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
Market Cap
$975.17M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$1.01B
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$1.03B
Return on Assets (ROA)
-1.53%
TTM Avg
-4.15%
3Y Avg
-5.20%
5Y Avg
-5.20%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $986.19M | -23.69% | -98.11% | -69.18% | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $1.00B | 19.92% | -50.75% | -41.99% | -34.79% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.00B | -0.20% | -7.25% | -2.02% | 0.01% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $999.08M | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | -10.18% | -8.89% | -12.61% | -16.81% |
| Immatics N.V. (IMTX)vs › | $1.01B | -43.17% | -16.38% | -11.13% | -30.16% |
| Aktis Oncology, Inc. (AKTS)vs › | $975.17M | -13.12% | -18.77% | -18.48% | -18.48% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -56.27% | -37.98% | -21.94% | -21.15% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | -1.53% | -4.15% | -5.20% | -5.20% |
| Teladoc Health, Inc. (TDOC)vs › | $1.04B | -6.43% | -17.46% | -82.63% | -55.94% |
ROA
-23.7%
ROE
-25.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -8.05% |
| 2024-12-31 | -188.17% |
| 2023-12-31 | -13.74% |
| 2022-12-31 | -66.76% |
